We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Anticipated Next Season of EGFR Inhibitors.
- Authors
Sequist, Lecia V.
- Abstract
EGFR‐directed therapy in lung cancer is here to stay, with new drugs targeting T790M‐mediated resistance coming quickly and the field continuing to advance. With greater access to sophisticated tools for interrogating both the somatic and germline genome, and with widespread acceptance of the scientific and clinical value of obtaining serial repeated biopsies from patients with oncogene‐addicted tumors, the field is poised to answer more nuanced questions.
- Subjects
PROTEIN kinases; GEFITINIB; ERLOTINIB; CELL receptors; EPIDERMAL growth factor; GENETIC mutation; LUNG tumors; GENETICS; THERAPEUTICS
- Publication
Oncologist, 2015, Vol 20, Issue 4, p335
- ISSN
1083-7159
- Publication type
Opinion
- DOI
10.1634/theoncologist.2015-0086